Cited by 211Genomics and Chromatin DynamicsCancer-related Molecular PathwaysLymphoma Diagnosis and Treatment

The c‐myc Promoter: Still MysterY and Challenge

Inken Wierstra, Jürgen Alves·2008·Advances in Cancer Research

Abstract

The transcription factor c-Myc is a key regulator of cell proliferation, cell growth, differentiation, and apoptosis. Deregulated c-myc expression possesses a high transformation potential and the proto-oncogene c-myc represents a promising target in anticancer therapy. This review on the c-myc promoter describes its organization, the different levels of its normal regulation (including initiation and elongation of transcription, the dual P1/P2 promoters, chromatin structure, c-Myc autosuppression) as well as its deregulation in Burkitt's lymphoma. Furthermore, it summarizes the many different transcription factors, signal transduction pathways, and feedback loops that activate or repress c-myc transcription. Finally, a concept for regulation of the c-myc promoter in different biological settings, for example, immediate-early induction, constant expression throughout the cell cycle in continuously cycling cells, repression during terminal differentiation and deregulation in cancer, is formulated.

Integrity signals

Registry

Crossref · 10.1016/s0065-230x(07)99004-1

Cites

1275 of 1275 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

3 retracted

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Wierstra, I., & Alves, J.
Affiliations
Medizinische Hochschule Hannover (DE)
Corresponding author
Inken Wierstra
Venue
Advances in Cancer Research
Publisher
Elsevier
Published
2008
Volume
99
Pages
113-333
ISSN
0065-230X (ISSN-L)
OpenAlex
W1870041030
Cited by
211
References
1,275
Citations by year
2025: 6 · 2024: 5 · 2023: 9 · 2022: 8 · 2021: 9 · 2020: 18 · 2019: 12 · 2018: 11 · 2017: 16 · 2016: 11 · 2015: 9 · 2014: 12 · 2013: 17 · 2012: 13
FWCI
15.49
Type
book chapter
Language
en
Open access
closed
Locations
  • Advances in cancer research (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
Keywords
c-Myc, c-myc promoter, transcriptional regulation, chromatin structure, Burkitt lymphoma, proto-oncogenes, signaling pathways, transcription factors, cell cycle, terminal differentiation
MeSH terms
Proto-Oncogene Mas, Animals, Burkitt Lymphoma, Chromatin, Gene Expression Regulation, Humans, Neoplasms, Promoter Regions, Genetic, Proto-Oncogenes, Repressor Proteins, Transcription Factors, Signal Transduction, Genes, myc

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review